Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

The effect of belumosudil on the therapeutic monitoring of tacrolimus and sirolimus in allogeneic hematopoietic transplantation

Dat Ngo, Jose Tinajero, Karamjeet Sandhu, Idoroenyi Amanam, Salman Otoukesh, Shukaib Arslan, Sunmin Park, Haris Ali, Badri Modi, Ryotaro Nakamura, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 7612.

https://doi.org/10.1182/blood-2025-7612

Published: 2025

Journal Articles

Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types

Klara Kim, Dat Ngo, Jose Tinajero, Dongyun Yang, Haoyue Shan, Karamjeet Sandhu, Haris Ali, Salman Otoukesh, Idoroenyi Amanam, Shukaib Arslan, Vaibhav Agrawal, Sunmin Park, Ryotaro Nakamura, Monzr M. Al Malki, Amandeep Salhotra

Blood (2025) 146 (Supplement 1): 935.

https://doi.org/10.1182/blood-2025-935

Published: 2025

Journal Articles

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Noushin Farnoud, Kamal Menghrajani, Paola Guglielmelli, Christopher Famulare, Erin McGovern, Giuseppe Gaetano Loscocco, Andriy Derkach, Andrew Dunbar, Naseema Gangat, Vikas Gupta, Andrea Arruda, Taghi Manshouri, Srdan Verstovsek, Andrew Kuykendall, Vincent Ho, Auro Viswabandya, Joachim Deeg, Thomas Monahan, Tania Jain, Jeanne Palmer, Alla Keyzner, Aaron Gerds, Alexandra Gomez-Arteaga, Nikolai Podoltsev, Roni Tamari, Helen Ajufo, Satyajit Kosuri, Haris Ali, Idoroenyi Amanam, Jordan Chervin, Minal Patel, Jesús Gutiérrez-Abril, Sarun Sereewattanawoot, Juan Arango Ossa, Francesco Passamonti, Francesco Maura, Maymona Abdelmagid, Ahmed Abdelrheem, Yassin Bashir, Muhammad Yousuf, Animesh Pardanani, Kapila Viges, David Shoultz, Rick Winneker, Omar Abdel-Wahab, John Mascarenhas, Ronald Hoffman, Ross Levine, Elli Papaemmanuil, Alessandro Vannucchi, Ayalew Tefferi, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2025-2046

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood (2025) 146 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2025-1024

Published: 2025

Journal Articles

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Blood (2025) 146 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2025-3352

Published: 2025

Journal Articles

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

Blood (2025) 146 (Supplement 1): 4305.

https://doi.org/10.1182/blood-2025-4305

Published: 2025

Journal Articles

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

Blood (2025) 146 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2025-2464

Published: 2025

Journal Articles

Itacitinib in combination with post-transplant cyclophosphamide and tacrolimus (ICT) as GVHD prophylaxis for reduced intensity matched donor peripheral blood stem cell hematopoietic cell transplantation: Interim analysis

Monzr M. Al Malki, Dongyun Yang, Sally Mokhtari, Anissa Bailey, Pooja Rajeevan, Rhiannon Imbeah, Salman Otoukesh, Brian Ball, Paul Koller, Vaibhav Agrawal, Yazeed Samara, Firoozeh Sahebi, Ibrahim Aldoss, Andrew Artz, Guido Marcucci, Stephen Forman, Ryotaro Nakamura, Haris Ali

Blood (2025) 146 (Supplement 1): 2455.

https://doi.org/10.1182/blood-2025-2455

Published: 2025

Journal Articles

Total marrow and lymphoid irradiation (TMLI) with fludarabine-melphalan (FM) conditioning for matched donor hematopoietic cell transplant (HCT) in older patients with Relapsed/Refractory (R/R) disease

Monzr M. Al Malki, Susanta Hui, Dongyun Yang, Sally Mokhtari, Hoda Pourhassan, Matthew Mei, Amanda Blackmon, Firoozeh Sahebi, Amandeep Salhotra, Brian Ball, Shukaib Arslan, Salman Otoukesh, Haris Ali, Guido Marcucci, Ryotaro Nakamura, Stephen Forman, Anthony Selwyn Stein, Jeffrey Wong

Blood (2025) 146 (Supplement 1): 376.

https://doi.org/10.1182/blood-2025-376

Published: 2025

Journal Articles

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Blood (2025) 146 (Supplement 1): 7353.

https://doi.org/10.1182/blood-2025-7353

Published: 2025

Journal Articles

Allogeneic hematopoietic stem cell transplantation for acute leukemias of mixed or ambiguous lineage

Blood (2025) 146 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2025-4282

Published: 2025

Journal Articles

Cytokine profiling identifies an IL‑8/IL1RAP‑Pathway–Linked inflammatory phenotype in myeloproliferative neoplasms (MPN) associated with high symptom burden and poor outcomes

Idoroenyi Amanam, Lucy Ghoda, Salman Otoukesh, Yile Zhou, Bin Zhang, Dauh-Lian Chi, Tim Synold, John Williams, Monzr M. Al Malki, Haris Ali, Guido Marcucci

Blood (2025) 146 (Supplement 1): 5593.

https://doi.org/10.1182/blood-2025-5593

Published: 2025

Journal Articles

Exploratory risk score incorporating donor type, MF-HCT high-risk mutations, and day 100 chimerism for outcome stratification in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Idoroenyi Amanam, Lucy Ghoda, Monzr M. Al Malki, Karamjeet Sandhu, Andrew Artz, Amanda Blackmon, Guido Marcucci, Stephen Forman, Ryotaro Nakamura, Salman Otoukesh, Haris Ali

Blood (2025) 146 (Supplement 1): 5592.

https://doi.org/10.1182/blood-2025-5592

Published: 2025

Journal Articles

Competing risk model of relapse versus non-relapse mortality in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Idoroenyi Amanam, Lucy Ghoda, Salman Otoukesh, Andrew Artz, Amanda Blackmon, Karamjeet Sandhu, Guido Marcucci, Stephen Forman, Ryotaro Nakamura, Monzr M. Al Malki, Haris Ali

Blood (2025) 146 (Supplement 1): 5591.

https://doi.org/10.1182/blood-2025-5591

Published: 2025

Journal Articles

First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation

Amandeep Salhotra, Jamie Wagner, Dongyun Yang, Haris Ali, Salman Otoukesh, Jemily Juan, Sindhu Saraswathy, Isaac Garcia, Dileshni Tilakawardane, Sunmin Park, Stephen Forman, Ryotaro Nakamura, Christine Brown, Enrique Montero

Blood (2025) 146 (Supplement 1): 276.

https://doi.org/10.1182/blood-2025-276

Published: 2025

Journal Articles

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Blood (2025) 146 (Supplement 1): 3795.

https://doi.org/10.1182/blood-2025-3795

Published: 2025

Journal Articles

Evolutionary divergence of polymorphic HLA residues predicts clinical outcomes after haploidentical stem cell transplantation in patients with AML

Blood (2025) 146 (Supplement 1): 512.

https://doi.org/10.1182/blood-2025-512

Published: 2025

Journal Articles

Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis

Blood (2025) 146 (Supplement 1): 2516.

https://doi.org/10.1182/blood-2025-2516

Published: 2025

Journal Articles

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia

Blood (2025) 146 (Supplement 1): 508.

https://doi.org/10.1182/blood-2025-508

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The effect of belumosudil on the therapeutic monitoring of tacrolimus and sirolimus in allogeneic hematopoietic transplantation

Post-transplant cyclophosphamide-based graft-verses-host disease (GVHD) prophylaxis is associated with a low incidence of fibrotic chronic GVHD after allogeneic hematopoietic cell transplantation across diverse donor types

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Clearance of RAS pathway mutations prior to allogeneic transplant in Acute Myeloid Leukemia are associated with favorable overall and leukemia free survival

Day 7 mount sinai acute GVHD international consortium (MAGIC) algorithm probability predicts GVHD and non-GVHD-related non-relapse mortality in a contemporary cohort of allogeneic transplant patients

Itacitinib in combination with post-transplant cyclophosphamide and tacrolimus (ICT) as GVHD prophylaxis for reduced intensity matched donor peripheral blood stem cell hematopoietic cell transplantation: Interim analysis

Total marrow and lymphoid irradiation (TMLI) with fludarabine-melphalan (FM) conditioning for matched donor hematopoietic cell transplant (HCT) in older patients with Relapsed/Refractory (R/R) disease

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Allogeneic hematopoietic stem cell transplantation for acute leukemias of mixed or ambiguous lineage

Cytokine profiling identifies an IL‑8/IL1RAP‑Pathway–Linked inflammatory phenotype in myeloproliferative neoplasms (MPN) associated with high symptom burden and poor outcomes

Exploratory risk score incorporating donor type, MF-HCT high-risk mutations, and day 100 chimerism for outcome stratification in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

Competing risk model of relapse versus non-relapse mortality in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation

First-in-human trial of allogeneic CD6-CAR tregs in patients with chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation

The activin receptor-like kinase-2 inhibitor zilurgisertib (INCB000928) as monotherapy or with ruxolitinib in patients with anemia due to myelofibrosis: Phase 1/2 study final results

Evolutionary divergence of polymorphic HLA residues predicts clinical outcomes after haploidentical stem cell transplantation in patients with AML

Outcomes of allogeneic hematopoietic cell transplant (HCT) in patients with TP53-altered acute leukemia or myelodysplastic syndrome: A retrospective single center analysis

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only